» Articles » PMID: 19005627

Use of Hand-held Dynamometry in the Evaluation of Lower Limb Muscle Strength in People with Huntington's Disease

Overview
Journal J Neurol
Specialty Neurology
Date 2008 Nov 14
PMID 19005627
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Sub-clinical muscle involvement, including myopathic changes and mitochondrial dysfunction of skeletal muscle, has been reported in people with Huntington's disease (HD). Muscle strength was evaluated using a hand-held dynamometer. Reliability and validity in people with HD were determined.

Method: Isometric muscle strength of 6 lower limb muscle groups was measured in 20 people with HD and matched healthy controls. People with HD were evaluated with the Unified Huntington's Disease Rating Scales (UHDRS). Within session reliability using intra-class correlation coefficients (ICC) was calculated. Discriminant and convergent validity was also evaluated.

Results: UHDRS motor scores of people with HD ranged from 28 to 80. Reliability of strength testing was excellent (ICC 0.86 to 0.98). People with HD had on average about half the strength of healthy matched controls. UHDRS motor scores and strength scores were significantly correlated (convergent) providing a further indication of validity of strength testing.

Conclusions: The hand-held dynamometer is a reliable and valid measurement tool to detect strength differences between people with HD and a matched control group. There is significant reduction in lower limb muscle strength in HD which does not appear to have been described previously.

Citing Articles

Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in .

Roth J, de Moraes R, Xu B, Crawley S, Khan M, Melkani G Front Aging Neurosci. 2023; 15:1223911.

PMID: 37823007 PMC: 10562706. DOI: 10.3389/fnagi.2023.1223911.


Huntingtin regulates calcium fluxes in skeletal muscle.

Chivet M, McCluskey M, Nicot A, Brocard J, Beaufils M, Giovannini D J Gen Physiol. 2022; 155(1).

PMID: 36409218 PMC: 9682417. DOI: 10.1085/jgp.202213103.


Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease.

Galyan S, Ewald C, Jalencas X, Masrani S, Meral S, Mestres J Sci Rep. 2022; 12(1):19642.

PMID: 36385140 PMC: 9668931. DOI: 10.1038/s41598-022-21900-2.


Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington's Disease.

Tomczyk M, Braczko A, Mierzejewska P, Podlacha M, Krol O, Jablonska P Cells. 2022; 11(17).

PMID: 36078070 PMC: 9454785. DOI: 10.3390/cells11172662.


Huntington's disease phenotypes are improved via mTORC1 modulation by small molecule therapy.

St-Cyr S, Child D, Giaime E, Smith A, Pascua C, Hahm S PLoS One. 2022; 17(8):e0273710.

PMID: 36037192 PMC: 9423655. DOI: 10.1371/journal.pone.0273710.


References
1.
Kilmer D, McCrory M, Wright N, Rosko R, Kim H, Aitkens S . Hand-held dynamometry reliability in persons with neuropathic weakness. Arch Phys Med Rehabil. 1998; 78(12):1364-8. DOI: 10.1016/s0003-9993(97)90311-7. View

2.
Wiles C, Karni Y, Nicklin J . Laboratory testing of muscle function in the management of neuromuscular disease. J Neurol Neurosurg Psychiatry. 1990; 53(5):384-7. PMC: 488053. DOI: 10.1136/jnnp.53.5.384. View

3.
Wiles C, Karni Y . The measurement of muscle strength in patients with peripheral neuromuscular disorders. J Neurol Neurosurg Psychiatry. 1983; 46(11):1006-13. PMC: 491736. DOI: 10.1136/jnnp.46.11.1006. View

4.
Verbessem P, Lemiere J, Eijnde B, Swinnen S, Vanhees L, Van Leemputte M . Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology. 2003; 61(7):925-30. DOI: 10.1212/01.wnl.0000090629.40891.4b. View

5.
Bohannon R . Test-retest reliability of hand-held dynamometry during a single session of strength assessment. Phys Ther. 1986; 66(2):206-9. DOI: 10.1093/ptj/66.2.206. View